AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
| 23.1 | Consent of Hall & Company relating to Innovus’ financial statements. |
| 99.1* | Current report on Form 8-K as filed on February 14, 2020 |
AYTU BIOSCIENCE, INC Exhibit
EX-23.1 2 f8k021320a1ex23-1_aytubio.htm CONSENT OF HALL & COMPANY RELATING TO INNOVUS\’ FINANCIAL STATEMENTS Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements (Form S-1 Nos 333-207421,…
To view the full exhibit click here
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.
